A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.

Abstract

OBJECTIVE:

To evaluate the effectiveness of vortioxetine in major depressive disorder (MDD) when used as a first-line versus second-line treatment or later.

METHODS:

This was a post-hoc analysis of three 3-month non-interventional, prospective studies of vortioxetine in MDD - REVIDA (Malaysia, Philippines, Singapore, Thailand), PREVIDA (Pakistan) and TREVIDA (Taiwan). Improvements in depressive symptoms (PHQ-9, CGI-S), cognitive function (PDQ-D) and work productivity (WPAI) were compared between studies, and in a pooled analysis of patients using vortioxetine as the first line versus second-line treatment or later. Safety was compared between studies.

RESULTS:

Overall, 798 patients were analyzed (PREVIDA = 425, REVIDA = 130, TREVIDA = 243). Most patients in PREVIDA (60.5%)/REVIDA (57.4%) used vortioxetine as first-line treatment versus TREVIDA (21.8%). Generally, greater improvements from baseline were observed across outcome measures in PREVIDA/REVIDA versus TREVIDA (Month 3, p < .0001). Vortioxetine as first-line treatment was associated with greater improvements in depression severity, cognition, functioning outcomes compared to second-line or later users (PHQ-9: -16.1 [6.4] vs -10.8 [8.9]; CGI-S: -2.7 [1.1] vs -2.0 [1.4]; PDQ-D: -29.5 [17.7] vs -18.5 [21.4]; p < .0001 at Month 3) as well as greater response (PHQ-9: 88.6% vs 61.5%; p < .0001) and remission rates (PHQ-9: 75.4% vs 47.7%; p < .0001). No new adverse events were reported outside of the product label.

CONCLUSIONS:

In the Asian real-world setting, vortioxetine showed greater improvements in depressive and cognitive symptoms, work functioning, and response and remission rates when used as first-line versus second-line treatment or later. Vortioxetine was well-tolerated irrespective of the study population across Asia.

• Authors: Rohini Bose, Syed Usman Hamdani, Fareed Aslam Minhas, Keira Joann Herr
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 38 Issue 5 Pg. 661-671 (05 2022) ISSN: 1473-4877 [Electronic] England
• PMID: 35049384 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antidepressive Agents
• Sulfides
• Vortioxetine

Topics

• Algorithms
• Antidepressive Agents (adverse effects)
• Depressive Disorder, Major (diagnosis)
• Double-Blind Method
• Humans
• Prospective Studies
• Sulfides (therapeutic use)
• Thailand
• Treatment Outcome
• Vortioxetine (therapeutic use)